RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL
Blood Podcast
00:00
A Phase II Study of Valamedostat and T Cell Lymphoma
Study included 25 patients with cytologically or pathologically diagnosed, relapsed or refractory ATL. They received oral Valametostat 200mg daily until progressive disease or unacceptable toxicity. The primary endpoint of the study was met, with an overall response rate of 48%. In a commentary, Dai Jihara said this trial provides hope for patients with advanced disease.
Transcript
Play full episode
